UnitedHealth Group (NYSE:UNH) Price Target Raised to $562.00

UnitedHealth Group (NYSE:UNH) had its price target boosted by Deutsche Bank Aktiengesellschaft from $545.00 to $562.00 in a report released on Friday, Benzinga reports. The firm currently has a buy rating on the healthcare conglomerate’s stock.

A number of other research analysts have also recently commented on UNH. StockNews.com cut shares of UnitedHealth Group from a buy rating to a hold rating in a research report on Thursday, April 18th. Truist Financial reiterated a buy rating and set a $600.00 price target on shares of UnitedHealth Group in a research report on Wednesday, April 17th. HSBC raised UnitedHealth Group from a reduce rating to a hold rating and set a $460.00 price objective for the company in a research note on Thursday, April 4th. Stephens reissued an overweight rating and set a $605.00 price objective on shares of UnitedHealth Group in a research note on Thursday, February 8th. Finally, Bank of America reissued a buy rating and set a $675.00 price objective on shares of UnitedHealth Group in a research note on Thursday, March 7th. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $570.05.

UnitedHealth Group Stock Down 2.0 %

UNH stock opened at $491.23 on Friday. The company has a current ratio of 0.85, a quick ratio of 0.79 and a debt-to-equity ratio of 0.69. The company’s 50 day moving average is $488.10 and its 200 day moving average is $515.03. The stock has a market cap of $452.88 billion, a price-to-earnings ratio of 30.03, a price-to-earnings-growth ratio of 1.38 and a beta of 0.54. UnitedHealth Group has a 1-year low of $436.38 and a 1-year high of $554.70.

UnitedHealth Group (NYSE:UNH) last posted its quarterly earnings data on Tuesday, April 16th. The healthcare conglomerate reported $6.91 earnings per share for the quarter, topping the consensus estimate of $6.63 by $0.28. UnitedHealth Group had a net margin of 4.05% and a return on equity of 26.50%. The company had revenue of $99.80 billion for the quarter, compared to analysts’ expectations of $99.23 billion. During the same period in the prior year, the business earned $6.26 earnings per share. UnitedHealth Group’s revenue for the quarter was up 8.6% compared to the same quarter last year. Sell-side analysts predict that UnitedHealth Group will post 27.61 EPS for the current fiscal year.

UnitedHealth Group Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 19th. Shareholders of record on Monday, March 11th were given a dividend of $1.88 per share. This represents a $7.52 annualized dividend and a yield of 1.53%. The ex-dividend date of this dividend was Friday, March 8th. UnitedHealth Group’s dividend payout ratio is currently 45.97%.

Insider Buying and Selling at UnitedHealth Group

In other UnitedHealth Group news, CAO Thomas E. Roos sold 858 shares of the firm’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $525.79, for a total transaction of $451,127.82. Following the completion of the transaction, the chief accounting officer now owns 32,289 shares of the company’s stock, valued at $16,977,233.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Erin Mcsweeney sold 1,236 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $483.48, for a total transaction of $597,581.28. Following the completion of the transaction, the executive vice president now directly owns 9,364 shares in the company, valued at $4,527,306.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Thomas E. Roos sold 858 shares of the firm’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $525.79, for a total value of $451,127.82. Following the transaction, the chief accounting officer now owns 32,289 shares of the company’s stock, valued at $16,977,233.31. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Institutional Investors Weigh In On UnitedHealth Group

Large investors have recently bought and sold shares of the business. Robbins Farley bought a new stake in UnitedHealth Group in the 3rd quarter worth about $25,000. Richelieu Gestion SA bought a new stake in UnitedHealth Group in the 4th quarter worth about $26,000. CGC Financial Services LLC grew its stake in shares of UnitedHealth Group by 1,000.0% during the 4th quarter. CGC Financial Services LLC now owns 55 shares of the healthcare conglomerate’s stock valued at $29,000 after purchasing an additional 50 shares during the period. True Wealth Design LLC bought a new stake in shares of UnitedHealth Group during the 4th quarter valued at about $31,000. Finally, NewSquare Capital LLC grew its stake in shares of UnitedHealth Group by 340.0% during the 3rd quarter. NewSquare Capital LLC now owns 66 shares of the healthcare conglomerate’s stock valued at $33,000 after purchasing an additional 51 shares during the period. 87.86% of the stock is currently owned by institutional investors.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.